TIM
NBIX icon

Tortoise Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Tortoise Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24
Closed -$3.37K – 995
2025
Q3 		$3.37K Buy
24
+3
+14% +$406 ﹤0.01% 771
2025
Q2 		$2.64K Buy
21
+9
+75% +$1.03K ﹤0.01% 743
2025
Q1 		$1.33K Hold
12
– – ﹤0.01% 738
2024
Q4 		$1.64K Hold
12
– – ﹤0.01% 773
2024
Q3 		$1.38K Hold
12
– – ﹤0.01% 798
2024
Q2 		$1.65K Hold
12
– – ﹤0.01% 795
2024
Q1 		$1.66K Buy
+12
New +$1.64K ﹤0.01% 788

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Tortoise Investment Management's NBIX Position: Q4 2025 in Review

Tortoise Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 24 shares — an estimated $3.37K sold.

Tortoise Investment Management first reported a position in NBIX in Q1 2024 and held it in 7 quarters. The position peaked at $3.37K in Q3 2025. 732 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Tortoise Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Tortoise Investment Management sold 24 Neurocrine Biosciences shares in Q4 2025, an estimated $3.37K.
  • Tortoise Investment Management first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 7 quarters.
  • Tortoise Investment Management's Neurocrine Biosciences position peaked at $3.37K in Q3 2025.
  • 732 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Tortoise Investment Management's 13F filing for Q4 2025, filed 6 Feb 2026.